Generex Biotechnology Corporation

535 articles with Generex Biotechnology Corporation

• Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

  4/29/2019

  Generex is pleased to announce that in the coming week, the company will finalize a financing commitment to advance the strategic goals of the company.

• Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern

  1/16/2019

  Management to Provide Update on Acquisitions, Financing, Expansion Initiatives & Strategic Plans

• Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen® Wound Conforming Gel Matrix with Three Dosage Options

  1/11/2019

  Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Olaregen Therapeutix Inc., a subsidiary of Generex Biotechnology will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue Based Product or CTP for wound healing.

• Generex Biotechnology Announces Acquisition of Surgical Supply and Distribution Company

  1/10/2019

  Medisource Partners is an FDA registered distributor with an extensive portfolio of medical and surgical products including bone grafts and biologics

• Generex Biotechnology Announces Investor Conference Call; Management to Provide Update on Acquisitions, Financing Initiatives & Strategic Plans

  1/10/2019

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Wednesday, January 16th, at 4:00 p.m. to update investors on the previously announced and pending acquisitions that offer significant value to the Generex parent company

• Generex Biotechnology Announces Acquisition of Surgical Device Manufacturer

  1/9/2019

  Pantheon Medical manufactures a line of FDA cleared products used in orthopedic surgeries including screws, plates, implants, and anchors

• Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.

  1/8/2019

  Closes transaction to complete 51% acquisition of Olaregen Therapeutix Plans Commercial Launch of FDA-cleared Excellagen®

• Generex Biotechnology Announces the Launch of a New Corporate Website

  1/8/2019

  Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company.

• Generex Biotechnology Completes Acquisition of Regentys Corporation

  1/7/2019

  Announces closing of 51% acquisition of regenerative medicine company Regentys™

• Generex Biotechnology CEO Joe Moscato Attending J.P. Morgan Healthcare Conference

  1/7/2019

  J.P. Morgan annual healthcare conference & biotech showcase to be held January 7 – 9 at the Westin St. Francis Hotel, San Francisco, CA

• Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology

  1/4/2019

  -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary.

• Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix

  1/3/2019

  Collagen Solutions & Berkshire Sterile Manufacturing to Supply Excellagen® for Q1 Launch

• Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen

  12/20/2018

  150+ Wound care consultants the core of national launch of Excellagen for the treatment of surgical wounds, diabetic foot ulcers, venous skin ulcers, and other hard to treat wounds

• Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

  12/14/2018

  Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”

• Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing

  12/13/2018

  Presents MATRIX Clinical Trial Data and Holds Clinical Advisory Board Meeting on the use of Excellagen for the Treatment of Diabetic Ulcers and Surgical Wounds

• Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer

  12/12/2018

  The combination study builds on previous clinical studies of both AE37 and Keytruda®. AE37, a cancer vaccine, was the subject of a 300 patient prospective, randomized and single-blinded Phase II study in patients with breast cancer.

• Generex Provides Stock Market Alert for December 10, 2018

  12/10/2018

  Generex Biotechnology Corporation completed payment of its 20 to 1 common stock dividend on November 30, 2018.

• Generex Posts Slides, Script & Recording of the December 3, 2018 Investor Conference Call

  12/4/2018

  Slide Deck and transcript available for download

• Generex Announces Acquisition of 100% of Hema Diagnostic Systems, Debt Restructuring & Warrant Deal

  12/3/2018

  Secures remaining 49% of HDS for $1.00

• Puration CBD Beverage Deal Bolsters Generex Topline and Overall Valuation

  11/30/2018

  Puration, Inc. (USOTC: PURA) today announced being featured in a Goldman Small Cap Research update on Generex Biotechnology Corp. (USOTC: GNBT)